• AXIOFILL is an acellular human placental extracellular matrix (ECM) derived from the placental disc
  • The product preserves multiple ECM components and other matrix-bound proteins
  • AXIOFILL is intended for use in replacement or supplementation of damaged or inadequate integumental tissue

Dry Particulate

Hydrated Particulate


  • Versatile: easy to apply dry or hydrate into paste
  • Scientific data supports preservation of ECM components and demonstrated cellular attachment1
  • Economic alternative for larger soft tissue deficits
  • Compatible with negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBOT)


AXIOFILL’s handling properties make it versatile for applying to complex, soft tissue deficits in its dry form, or as a paste. Clinical use examples may include:


  • Surgical debridement

  • Partial and full thickness wounds

  • Diabetic Foot Ulcers (DFUs)

  • Venous Leg Ulcers (VLUs)

  • Pressure Ulcers (PUs)

  •  Chronic vascular ulcers

  • Trauma wounds (abrasions, lacerations, burns, and skin tears)

  • Draining wounds


  • Tunneling/undermined wounds
  • Fistulae
  • Deep, irregular wounds
  • Incisions
  • Surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence)
  • Other procedures 

Usage for large, deep defects and incisions

Hydrates easily to apply as a paste

AXIOFILL Processing & Details

AXIOFILL is processed using PURION, a unique patented method for placental-based allografts according to standards and/or regulations established by the American Association of Tissue Banks (AATB) and the United States Food & Drug Administration (FDA). The product is derived from placental tissue donated by healthy, consenting mothers who have given live Caesarean section births in the US. 

MIMEDX’s PURION patented process preserves extracellular matrix components, including regulatory factors and other matrix-associated proteins. For an additional level of safety, the product is terminally sterilized.


Decellularized, Biocompatible Scaffolding2
IHC staining for specific ECM molecules, as indicated in the particulate final AXIOFILL product. Brown coloration indicates reactivity with antibody probe.3

AXIOFILL restores site-appropriate and functional tissue by providing an environment conducive for cellular integration and remodeling.1

Clusters of dark pink-colored cells indicate formation of neovascularization throughout implant. 

1. Data on file. MIMEDX Research Report. MM-RD-00113: Non-GLP Evaluation of Placental Based Products for Cellular Response in a Mouse Subcutaneous Implant. 2. Data on File. MIMEDX Research Report. MM-RD-00112: Placental Collagen Matrix Development Phase Report. 3. Data on File. MIMEDX Research Report. MM-RD-00105: Placental Collagen Matrix Feasibility Report. 

Contact us for more information about AXIOFILL


AXIOFILL Product Brochure

AXIOFILL Application Guide